Purpose; We have performed a phase I study of the cytotoxic immunoconjugate CMB-401 in women with epithelial ovarian cancer (EOC). CMB-401 is a directed chemotherapy that comprises a genetically engineered human antibody against polymorphic epithelial mucin, to which is attached covalently two to three molecules, on average, of the cytotoxic antibiotic calicheamicin. The primary objectives of this two-centre study were to identify end-organ toxicities and to establish the maximum tolerated dose (MTD).
Introduction
Ovarian cancer is the most common malignancy of the female genital tract in the developed world. Worldwide there were an estimated 160,000 cases in 1985. [1] . Epithelial tumours are the most frequent, accounting for approximately 80%-90% of all ovarian tumours [2] . The current prognosis for patients diagnosed with ovarian cancer is variable depending on the country of presentation [3] . In the UK the overall five-year survival is only 30% [4] . This low survival figure is confirmation of a disease that is usually diagnosed at an advanced stage and of the limitations of current screening and treatment modalities. Standard therapeutic modalities include surgery, chemotherapy and occasionally radiotherapy. Much effort has been spent on improving the surgical care, developing new cytotoxic agents and refining chemotherapeutic regimens. These developments will continue, and improved care and prognosis of patients with many cancers can be expected. However, it is likely that novel treatments will be required in the future if the outcome of treatment is to improve significantly.
In the last decade there has been increased interest in the development of anti-cancer immunotherapies. This stems from the general improvements in understanding of antigen presentation, humoral and cellular immunity, the role of cytokines in the immune response and specifically from the identification of a number of putative tumour associated antigens (TAA) expressed by a variety of human cancers.
Polymorphic epithelial mucin (PEM), a high molecular weight glycoprotein, is one potential TAA. It is expressed on the luminal surfaces of normal epithelial cells [5] and is known to be up regulated in normal breast epithelium during pregnancy and lactation. In addition, PEM is known to be up regulated and expressed on the cellular surface in a number of cancers of epithelial origin, including breast and ovarian carcinomas -with expression in over 90% of tumours [6] .
The gene that encodes the PEM molecule has been cloned and termed MUCl [7] . The MUCl gene sequence is the same for the core protein component of PEM, whether the PEM is expressed on a carcinoma cell or a normal cell. The contrast in PEM expressed by tumour cells is in the structure of the carbohydrate molecules involved in glycosylating the protein core. In normal PEM these carbohydrate side chains are longer and form a repeating polylactosamine structure [8, 9] . In tumour associated mucin the side chains are much shorter leading to the exposure of core protein epitopes that are normally masked. The development of techniques for producing monoclonal antibodies with specificity against TAA has led to trials of passive immunotherapy with antibodies in cancer patients. Given unmodified, monoclonal antibodies may be able to facilitate tumour rejection by complement activation, antibody-dependent cellular cytotoxicity or induction of the anti-idiotypic network. Such an approach has been used with some success in colorectal cancer patients [10] . In patients with ovarian cancer murine monoclonal antibodies have previously been used. Unfortunately, these antibodies induce a host immune response leading to the production of human anti-mouse antibodies (HAMA), which may affect the predicted pharmacokinetics or inactivate the injected monoclonal antibody and prevent repeated administration. Alternatively, monoclonal antibodies can be conjugated to cytotoxics or radionuclides prior to administration. In these circumstances the antibody acts as a delivery system for the conjugate -selectively targeting the cell which presents the TAA -thereby increasing therapeutic efficacy. It is this approach that we have adopted in the current study, using PEM as the target TAA in patients with epithelial ovarian cancer.
CTMO1 is a murine monoclonal antibody, which is directed against PEM activity [11] . In an attempt to overcome the HAMA response and allow repeated administration to human subjects, the complementarity determining regions (CDR) of this antibody were grafted into human acceptor framework sequences of immunoglobulin (IgG4) [12] . The resulting recombinant molecule, hCTMOl, is virtually indistinguishable from a human immunoglobulin and has PEM binding characteristics which are similar to those of CTM01. A previous biodistribution study has confirmed the potential of hCTMOl as an internalising drug carrier [13] in patients with ovarian cancer.
For the present study hCTMOl was conjugated to the cytotoxic antibiotic, N-acetyl-yl' 1 calicheamicin. Preclinical studies evaluating the hCTMOl-calcheamicin immunoconjugate (CMB-401) have shown in vitro and in vivo activity against ovarian carcinoma [14] . In this article we report the first clinical study using CMB-401 in patients with epithelial ovarian cancer (EOC). The primary objective of this study was to evaluate the endorgan toxicity of ascending doses of the immunoconjugate CMB-401; thereby establishing the maximum tolerated dose (MTD) in patients with EOC. Patients were also monitored for evidence of tumour response. The pharmacokinetics and immunogenicity of CMB-401 were evaluated in these patients, and these data are reported elsewhere.
Patients and methods

Study design
This study was a dual-centre, open label, sequential ascending dosage group study designed to evaluate end-organ-toxicity and establish the highest safely tolerated dosage level (MTD) of CMB-401, which was acceptable in patients with advanced ovarian cancer. Patients were recruited from the Departments of Clinical Oncology at Weston Park Hospital, Sheffield, UK, and City Hospital, Nottingham, UK. The appropriate regulatory authority approvals were obtained prior to the commencement of the study. The local ethical committees for each recruiting centre approved the study protocol and all subsequent amendments and were informed of all dose escalations. The study was conducted in accordance with current European Guidelines on Good Clinical Practice and patients were treated according to the principles of the Declaration of Helsinki. Written informed consent was obtained from each patient prior to entry into the study.
Patient population
A total of 34 patients were recruited to this study -17 from each participating centre. Women with persistent or recurrent histologically confirmed EOC refractory to or unsuitable for platinum/standard therapy; aged 20-75; with a WHO performance status of 0-2; life expectancy of more than three months and fulfilling other standard eligibility criteria were entered into this trial. The median patient age was 57 years (range 37-75 years). The patient characteristics in terms of performance status, histological type, FIGO stage and prior radiotherapy are listed in Table 1 . Invariably patients were diagnosed after histological analysis of samples obtained at the initial surgical procedure. The surgical procedures were performed at various hospitals in the catchment area of each recruiting centre. Eleven of thirty-four patients had a total of fifteen radiotherapeutic interventions prior to trial entry. All patients had received previous chemotherapy and were deemed to be either unsuitable for further standard therapy prior to entry into the trial, or wished to receive a novel agent that was unlikely to be associated with typical chemotherapy-related toxicities, e.g., alopecia. neutropaenic sepsis. In brief, patients had received a mean of 3.2 (median 2, range 1-12) previous chemotherapeutic regimens with a median interval since last chemotherapy of 182 days (range 34-1217 days). All patients had received previous platinum therapy with a mean of 1.67 regimens (median 2, range 1-3 regimens) Engineered human antibody hCTMOl, N-acetyl-yl/ 1 , calicheamicin and CMB-401 hCTMOl was constructed and provided for this study by Celltech Therapeutics Ltd, Slough, UK. hCTMOl was formed by grafting the CDR of the murine monoclonal antibody CTMO1 into an otherwise virtually human immunoglobulin (kappa light chain; gamma 4 heavy chain) using the pAL55 single expression vector. The vector was transfected into the non-secreting myeloma cell line NSO and subsequently cell lines with the highest antibody production rate were amplified and cloned. The specificity and binding characteristics of the resultant hCTMOl antibody were found to be equivalent to the murine CTMO1.
Dimethyl
For this study, hCTMOl was conjugated by Wyeth-Ayerst Research, Pearl River, USA, to the N-acetyl-yl/' analogue of calicheamicin using an amide-based linkage to form the cytotoxic immunoconjugate CMB-401 ( Figure 1 ). The calicheamicins are a family of naturally derived toxic antibiotics originally isolated from a broth extract of a soil micro-organism, Micromonospora echinospora calichensis.
calicheamicin is the most potent member of the family and exerts its toxic effects by binding to the minor groove of DNA and causing sequence-specific, double-stranded DNA cleavage [15, 16] .
Drug supply and administration
Patients received at monthly intervals up to four cycles of a dual infusion of 35 mg/m 2 hCTMOl 'pre-dose' followed by ascending doses of CMB-401 -a regimen which minimises drug uptake in normal tissues whilst enhancing delivery to the ovarian tumour [17] . A conservative starting dose of 2 mg/m 2 CMB-401 was chosen for the first patient cohort. This corresponds to approximately one tenth of the lowest toxic dose in the rat and allows for the uncertainties associated with a highly novel toxic antibiotic whose toxicity may still be localised unexpectedly in patients by hCTMOl.
hCTMOl was supplied in glass vials as a sterile, pyrogen-free clear solution. Patients received 35 mg/m 2 intravenously as a 15-minute infusion. The drug was administered to the patients using a PCI IMED pump via a filter (IVEX-filter extension set, 1.2 um). One hour after starting the hCTMOl infusion the patients commenced a one hour infusion of the immunoconjugate CMB-401. CMB-401 was supplied as a sterile, endotoxin-free, white lyophilized powder in amber glass vials, which were refrigerated and protected from light until use. The drug product was reconstituted with 2.5 ml sterile water for injection before mixing with 0.9% sodium chloride for injection and human serum albumin prior to administration. Patients received the appropriate dose of the drug as a 100 ml infusion over one hour via a PCI IMED pump and filter set covered with an ultra violet lightinhibiting bag.
Study procedures
Patient safety and toxicity assessments
Eligible patients were admitted for an overnight stay after receiving their infusion of the study drug. Patients were reviewed weekly. Four weeks after each drug administration patients became eligible for a further infusion up to an arbitrary maximum of four doses. After their final dose of CMB-401 each patient was seen weekly for four weeks and then fortnightly until eight weeks post-drug administration when follow up was concluded.
A full physical examination was performed at each patient visit. Additional observations (blood pressure, heart rate, respiratory rate and temperature) were performed around the time of each drug infusion, and investigations performed on each patient visit included: full blood count (FBC) and differential, coagulation screen, urea and electrolytes, creatinine, calcium, liver function tests, serum amylase, urinalysis and an electrocardiograph (ECG).
The toxicities experienced by patients entered onto this study were assessed using the WHO toxicity rating scale. Toxicities not covered by this rating scale were also documented and graded as mild, moderate or severe with severe equating to grade 3 WHO toxicity. The dosage level of CMB-401 administered to subsequent patient cohorts was planned to be increased by 100% per cohort unless evidence of toxicity was observed, defined as an increase in one grade in any parameter in the WHO toxicity rating scale. In those circumstances the dosage level for subsequent patient cohorts was increased by 50%. If an increase of two grades in any toxicity was observed subsequent dose increases were only 25%. A full description of the dose escalation scheme adopted in this trial is provided in Table 2 . Dose limiting toxicity and MTD were also strictly defined at the outset of the trial. The MTD was reached when two out of six patients at a dosage level developed WHO grade 3 toxicity or one out of six developed WHO grade 4 toxicity.
Tumour response
Tumour response to CMB-401 was subjectively monitored throughout the course of this study by repeated clinical examination. Objective assessment of tumour response was not a primary endpoint of this phase I study. However, serial measurements of serum tumour markers (CA125) and computed tomography (CT) assessment of residual disease dimensions were performed before the patient was entered into the trial and at eight weekly intervals whilst the patient was participating in the study. Patients were only eligible for further treatment cycles if there was no evidence of disease progression.
Pharmacokinetics and immunogenicity
Blood samples to assess the pharmacokinetics and immunogenicity of CMB-401 were taken around the time of drug administration and at each subsequent patient visit. The results from this part of the study are reported elsewhere.
Results
CMB-401 dose escalation
Each patient cohort consisted of three patients. The starting dose of CMB-401 was 2 mg/m 2 and increased to the MTD at 16 mg/m 2 via seven patient cohorts. A total of 12 patients were entered into the study at the MTD. Only one patient with prolonged thrombocytopaenia after a dose of 10 mg/m 2 discontinued treatment prematurely.
Patients in the first two cohorts experienced a number of minor grade 1 toxicities restricting the dose escalation to 50% for the subsequent cohort. In the third cohort one patient experienced a grade 2 fever with drug administration and after this all patients received prophylactic paracetamol and chlorpheniramine prior to further CMB-401 infusions. One further patient in this cohort experienced grade 3 nausea and vomiting. With higher doses this became a universal feature and prophylactic anti-emetics were introduced. 8 mg intravenous dexamethasone was used as it was felt this would also ameliorate any potential hypersensitivity responses to CMB-401. Patients in the fourth cohort experienced minor toxicity only. However, the fifth cohort was extended to six patients due to the toxicities experienced by the initial three patients (two of three had transient grade 2 thrombocytopenia and one of three had transient grade 2 leucopenia/grade 3 granulocytopenia). A further 25% dose escalation was agreed for the sixth cohort. The patients in this cohort experienced numerous grade 1 toxicities and one had a transient grade 2 thrombocytopenia, and on this basis a further dose escalation was adopted for the seventh patient cohort.
Three patients were initially entered in cohort 7. All patients experienced moderate or severe malaise following drug administration. In addition, the first patient experienced transient grade 2 thrombocytopenia and the second a transient grade 2 elevation in transaminases. The third patient experienced a grade 3 elevation in transaminases -however, due to an infusion error this patient had actually received 20 mg/m 2 of CMB-401. This toxicity was however considered relevant to the future conduct of the trial and therefore this cohort was extended to gain further experience at the 16 mg/m 2 dose level.
A further four patients were entered at the 16 mg/m 2 dose level before a decision was made regarding further dose escalation. One of these patients, whilst meeting the study entry criteria, had rapidly progressing disease and died 11 days following the administration of CMB-401. This patient's death was unequivocally ascribed to Number of patients experiencing grade 3-4 haematological toxicities Haemoglobin disease progression and data from this patient were excluded from decisions on possible further dose escalation. Of the other three patients added to cohort 7, two experienced severe malaise, one experienced grade 2 diarrhoea and another grade 2 thrombocytopenia following CMB-401 administration. At this stage of the trial (16 mg/m 2 dose level) there was a consensus reached that patients' experience of fatigue and malaise following CMB-401 was so consistent and of such severity that, together with the other toxicities the patients had experienced, no further dose escalation could be justified. The MTD was defined at 16 mg/m 2 and, in agreement with the protocol, an additional six patients were added to this cohort until a total of 12 patients had received this dose. Additionally, the MTD cohort also contained the patient who received 20 mg/m 2 .
Toxicity
Haematological toxicity Leucocytes/'granulocytes. Neutropaenia was not a serious dose-limiting toxicity. Grade 3-4, respectively, leucopaenia and neutropaenia were experienced by 2 of 34 and 3 of 34 patients respectively, with a nadir at 7-14 days post-drug administration before recovering prior to administration of the subsequent treatment cycle. The reduction in white blood counts was rarely clinically relevant. Only 1 of 34 patients developed neutropaenic sepsis, and this occurred at the same time as DIC and haemorrhage from her tumour mass.
Platelets. Three patients in the final treatment cohort experienced grade 3-4 thrombocytopenia, with a platelet nadir at seven days with subsequent recovery prior to further drug administration. It was noted that this effect was cumulative: recovery became less complete in patients receiving three or four treatment cycles. One patient (10 mg/m 2 ) could not receive a fourth treatment cycle, as her platelet count did not recover.
Haemoglobin. As can be seen from Table 3 , 7 of 34 patients experienced grade 3^4 toxicity with 4 of these patients being in the final 16 mg/m 2 cohort. In two patients this was attributed to the disease status of the patients, while in the other two patients this was due to significant gastrointestinal haemorrhage.
Haemorrhage. Four patients (three at 16 mg/m 2 and one at 10 mg/m 2 ) experienced haemorrhage during the study, unrelated to any abnormalities of coagulation. One patient had a gastro-intestinal haemorrhage after receiving four cycles of CMB-401. Appropriate therapy and transfusion support was instituted, but the patient suffered a cerebro-vascular accident (CVA) and subsequently died. A CT scan of the head performed prior to the patient's death suggested a brain stem infarct. The second patient had a large upper abdominal tumour mass infiltrating the small and large bowel at trial entry. Three weeks after receiving her first cycle of CMB-401 the patient bled from the tumour into the associated bowel. Despite appropriate therapy the patient's condition deteriorated significantly and she developed disseminated intravascular coagulation (DIC) in association with septicaemia as a terminal event.
After their participation in the study was concluded, two patients experienced episodes of haemorrhage: Following a final cycle of CMB-401, one patient suffered a general deterioration in condition and finally died nine weeks later. As a terminal event the patient was admitted with strange affect/confusion and reported altered stool colour. A post-mortem performed on this patient revealed carcinomatosis from bilateral serous adenocarcinoma of the ovaries and intestinal angiodysplasia. Three sites of angiodysplasia were identified in the stomach, caecum and the rectum. The other patient received three cycles of CMB-401 at a dose of 10 mg/m 2 , and would have been eligible for a full four treatment cycles. However, she developed persistent thrombocytopenia (grade 1-2) following her third cycle and so was withdrawn from the trial five weeks after receiving her third cycle of the trial drug. She was admitted on three occasions with episodes of gross/frank haematuria. Investigations including cystoscopy showed radiation induced telangectasia (the patient had previously had pelvic irradiation) but no other abnormalties were identified.
Non-haematological toxicities
Malaise. The most significant drug related toxicity experienced by patients during this trial was malaise. Whilst malaise was reported in some patients entered into the early patient cohorts, the effect became a universal feature in the final two patient cohorts and was classified as severe in the majority of patients receiving 16 mg/m 2 . Typically, patients experienced symptoms of fatigue and non-specific malaise commencing 48 hours post-CMB-401 administration. These symptoms commonly lasted for 7-10 days during which time the patient would be significantly disabled and require assistance with activities of daily living. Occasionally the symptoms were more prolonged and there was some evidence of cumulative toxicity with these symptoms being more severe in second and subsequent treatment cycles in patients receiving higher doses of CMB-401. It was concluded that these effects were related to drug administration and were of sufficient importance that they should be included in the definition of the MTD.
Liver function. During the course of the trial, liver function was assessed by serial measurement of AST, ALT, alkaline phosphatasc and bilurubin. Transient elevations of serum transaminases were commonly observed in patients in the first week following CMB-401 administration. Typically these elevations were most pronounced after the first cycle of the study drug. However, these changes were rarely of any clinical significance, with only one and nine patients experiencing grade 3-4 or grade 2 elevations in AST, respectively. One patient suffered a general deterioration in her condition after receiving four cycles of the study drug and subsequently died nine weeks after receiving her final treatment. During this time period her liver function deteriorated and at post-mortem the liver was of small size with evidence of zone three necrosis, consistent with poor perfusion/hypovolaemia for which no clear cause could be identified.
Renal toxicity. Renal toxicity was not a significant problem, but in two patients deterioration in renal function did occur. One patient showed progressive elevation of serum creatinine following two cycles of CMB-401. Because of disease progression treatment was discontinued, and the deterioration in renal function continued during subsequent treatment with topotecan. The patient's eventual death was ascribed to disease progression. Another patient had an increase in serum creatinine during three cycles of CMB-401, which continued further after treatment. This deterioration was still present at the time of the patient's death, which was attributed to disease progression. Mild proteinuria was experienced in a number of patients, although this was invariably associated with contaminated specimens or urinary tract infections. Haematuria was occasionally observed, however, this was never significant (except for the patient described previously) and was usually associated with doubt over the organ of origin of the blood.
Nausea and vomiting. CMB-401 administration was associated with nausea and with 26 of 34 patients entered into this trial experiencing grade 3 toxicity. After the initial patient cohorts it became clear that prophylactic anti-emetic therapy would be required. The standard first-line oral anti-emetics were used, i.e., metoclopramide or prochlorperazine. However, as the dose of CMB-401 increased it was obvious that this was insufficient to obtain satisfactory anti-emetic control. Intravenous dexamethasone was therefore infused prior to administration of the study drug. This form of anti-emesis was chosen as it was felt that the dexamethasone would also help control any potential allergic type responses. In Sheffield, a step-wise approach to emesis control is adopted, and as such, in line with hospital policy, a multi-drug regimen including oral haloperidol and lorazepam in addition to dexamethasone was adopted as standard therapy for the remainder of this trial. This regimen generally achieved good emesis control, and in those few patients in whom it did not (usually in patients who had previously experienced a significant emesis with other cytotoxic regimes), 5-HT 3 antagonists were used to good effect.
Fever with drug. Minor degrees of fever with drug administration were observed in a small number of patients in the early part of this trial. However the introduction of a pre-medication regimen successfully ameliorated this problem, with none of the patients in the sixth or seventh cohort experiencing grade 2 toxicity or above.
Other adverse events. Other adverse events were documented serially throughout the course of the trial according to the WHO toxicity rating scale. Grade 3-4 events rarely occurred and were always attributable to disease status/progression rather than to a drug-induced effect. In particular 8 of 34 and 2 of 34 patients had grade 3-4 disease-related constipation and pulmonary complications. The patient who experienced the CVA was classified as a grade 4 neurotoxicity.
Tumour response
Serial CA125 evaluation and CT/ultrasound imaging provided objective assessments of tumour response to the study drug. Between patients, CA125 values at study entry varied over a considerable range reflecting both the extent of disease and the level of CA125 expression in a given tumour. Two patients at a dose of 10 mg/m 2 and two at 16 mg/m 2 showed greater than 50% reductions in CA125 values during the course of the study. These patients had a platinum free interval of 55, 713, 278 and 293 days, respectively). One of these patients has experienced her longest period of disease control despite previous rapid progression (<6 months) after first line carboplatin and second-line paclitaxel. CA125 levels remain below their pre-treatment value with no clinical evidence of progression more than two years after CMB-401.
In addition, imaging evidence of tumour response was seen in three patients, although none reached the criteria for a partial remission. In one patient a liver metastasis reduced in size from 4 x 3.5 cm to 4 x 2 cm and there was a reduction in ascites; in a second a pelvic mass reduced in size from 6 x 7 cm to 6 x 5 cm, while in the third patient a pelvic mass reduced in size from 11 x 11 cm to 9 x 7 cm. These patients received 10 mg/m 2 , 12.5 mg/m 2 and 16 mg/m 2 doses of CMB-401 with a platinum free interval of 174, 244 and 293 days, respectively.
Discussion
hCTMOl is an engineered human monoclonal antibody that is internalised into cells expressing its target antigen, PEM. The antibody has no inherent antitumour activity but has been conjugated to the potent cytotoxic antibiotic N-acetyl-yl/'-calicheamicin [15, 16] to form the immunoconjugate CMB-401. Administered alone yl/ 1 calicheamicin is too toxic to be therapeutically beneficial, however the antibiotic's low molecular weight makes it an appropriate candidate for antibody targeted therapy. An amide based linkage of hCTMOl to the N-acetyl-yl/ 1 analogue of calicheamicin was chosen on the basis of experimental data suggesting that this immunoconjugate was efficacious with an acceptable therapeutic window [14] . Toxicology studies with calicheamicin itself or as the immunoconjugate show similar degrees of toxicity -although the profiles of organ damage were somewhat different reflecting the longer circulating half-life of the conjugate. However, the conjugate is much more toxic to tumour cells than the unconjugated calicheamicin (Celltech -data on file).
This immunoconjugate is therefore designed to target this cytotoxic agent to cells that express PEM where the molecule is internalised and exerts its cytotoxic effect by site-specific, double-stranded DNA cleavage. Ninety percent of EOC tumours overexpress PEM on the tumour cell surface and therefore this tumour type is a suitable target for trial therapy with the CMB-401 immunoconjugate, with further evidence to support this provided by a previous biodistribution study [13] . This paper reports the first phase I trial with the CMB-401 immunoconjugate in patients with EOC.
CMB-401 was generally well tolerated in this patient group. Transient debilitating malaise and emesis were commonly experienced, necessitating the use of prophylactic therapy to control the latter symptom. WHO grade 3-4 toxicities, irrespective of causality, included: haematological (anaemia 21%, granulocytopenia 9%, thrombocytopenia 9%); liver and renal (transaminases 3%, alkaline phosphatase 6% and urea 3%); sepsis 3% and haemorrhage 6%. MTD was defined at 16 mg/m 2 by malaise, haematological toxicities and the experience of gastro-intestinal haemorrhage. This latter symptom is a cause of concern and will be monitored closely in future drug development. However, there was little targeting of the gut in previous biodistribution studies [13] , and causality with the study drug is unlikely.
Whilst assessment of anti-tumour activity of CMB-401 was not a primary objective of this study, it was encouraging to note initial evidence of activity against EOC. From a dose of 10 mg/m 2 and above three patients had imaging evidence of a reduction in tumour bulk and four had greater than 50% falls in CA125 level. This activity occurred in a heavily pre-treated patient group. The antibody hCTMOl has no known antitumour activity by itself and these effects on tumour volume are attributable to the cytotoxic portion of the conjugate.
The use of immunotherapeutic treatment approaches in ovarian cancer is still in its infancy. However rapid advances in the fields of molecular biology, biotechnology, immunology, adoptive immunotherapy and cytokine biology, have resulted in many reagents becoming available for evaluation [18] . Various experimental treatment approaches have been tested and, in particular, the patient population with small volume residual peritoneal disease could benefit from such strategies. In conclusion this study has established that the cytotoxic immunoconjugate CMB-401 appears to have an acceptable toxicity profile with initial evidence of activity against EOC. Based on the experience of this phase I trial, in a phase II trial of CMB-401 in Europe and North America of CMB-401 at 16 mg/m 2 in patients with ovarian cancer has been instituted.
